zoeti spun lead global manufactur medic vaccin
livestock revenu companion anim revenu
continu impress consist zoetiss earn better
expect result driven oper growth includ
organ oper growth exclud abaxi acquisit despit tougher
companion anim comp continu gener double-digit growth
 intern apoquel sale increas y/i cytopoint
increas simparica sale increas y/i cross
blockbust threshold quarter ytd sale face
tougher livestock comp fewer intern day
headwind maintain buy rate rais price target
believ long-term growth outlook fundament remain solid
nutshel adjust ep higher consensu
higher estim revenu increas
higher consensu
higher estim organ oper growth
driven price volum fx creat bp headwind
companion anim oper revenu growth driven
 growth intern growth livestock sale increas
oper vs forecast driven growth
intern growth gross margin improv bp y/i
bp higher estim
ep guidanc rais revenu narrow toward upper end
rang guidanc updat follow due strong result
oper companion anim revenu increas oper
strong growth driven increas sale key dermatolog
product apoquel cytopoint new parasiticid simparica
driven growth swine vaccin time purchas china
cattl growth brazil due local consumpt increas export
page
period except per share revenueadj epsrevenueadj epsrevenueadj epsrevenueadj previou revis compani data factset estim craig-hallum capit group llc guidancelowhighlowhighrevenu revenue tax oper compani reportsupdatedprevi
livestock growth driven poultri swine fish total livestock revenu
increas oper growth off-set fx headwind
driven oper growth swine oper growth poultri
oper growth fish oper growth cattl cattl sale
actual due resumpt competitor vaccin
continu soft dairi market expect cattl market improv
compani data craig-hallum capit group llc estim
dermatolog product revenu increas y/i
sequenti driven apoquel sale
cytopoint sale
dermatolog revenu increas y/i
dermatolog sale increas y/i market penetr
dermatolog product increas vs previous state
penetr intern market significantli lower
dermat season strong growth expect moder
simparica revenu increas y/i simparica revenu
increas y/i intern sale simparica increas
sale driven strong flea tick season
expect moder somewhat complet regulatori file
requir set forth fda oral triple-combo known simparica trio
combin sarolan activ ingredi simparica two
activ ingredi treat intern parasit heartworm prevent
expect simparica trio approv market
exhibit revenu intern market
page
varianc varianc except per share c-h estimate con actualto c-h estimate c-h estimate revenu growth driven strong companion anim growth includ monthsy/i abaxi acquisitionu companion dermatolog portfolio simparica contribut growth older in-liney/i growth declin due competitionu livestock driven sale poultri swine product off-set lowery/i growth due resumpt competitior vaccin weak dairi market ernat oper revenu increas driven strong companion anim sale growthy/i oper headwind total revenu w/ brazil largest impact companion saw growth sever market key dermatolog product simparica strongholdy/i cat contribut month abaxisoper oper growth int livestock driven swine vaccin sale europ y/i time custom purchas china strong emerg market demand oper anoth strong market recoveri trucker strike exportscontract oper revenu increas excl abax driven price volumey/i volum growth came new product came key dermatologyoper million australiabrazilcanadachinafr germani italyjapanmexicospainuk compani report craig-hallum capit group
revenu increas y/i higher
estim oper growth beat
estim fx neg impact
livestock revenu increas
higher estim driven oper
growth vs estim fx headwind
companion anim revenu increas y/i
higher estim driven
oper growth vs estim partial off-set
fx impact strong companion anim growth driven higher
dermatolog new product simparica sale across variou
market well increas medic rate china brazil
countri perspect oper cc growth strongest brazil
 mexico spain itali china
livestock growth benefit recoveri sale
delay end due nation truck driver strike brazil
ship resum earli exclud time benefit oper growth
brazil would rang
compani data craig-hallum capit group llc estim
revenu speci continu reflect strong growth companion anim
product like apoquel cytopoint simparica driven dog cat
zoeti inc page
quarterli i/ varianceactualc-h estimate variancevari million except per expect revenu driven oper growth includ growth ofchang intern oper growthchang margin continu expand nice track achiev bp gross base year increas due abaxi acquisit increas comp-rel cost increas due mab invest chronic pain pipelin programsamort oper oper oper expens higher due debt offer abaxi acquisitionincom tax rate lower expect due tax reform one-tim discret item tax rate expect year increas net incom attr incom attribut count modestli lower expect spent buy-back sharesdepreci ebitda analysi oper incom attr
revenu percent total year ago cattl sale
decreas bp revenu due increas competit weak
dairi market isnt expect improv swine revenu decreas
bp total fish increas bp y/i driven strong
organ growth sale brazil
exhibit revenu speci
guidanc updat adjust guidanc follow
compani data factset data system craig-hallum capit group llc estim
tweak estim due increas interest expens flow
attribut billion note offer complet august
conjunct abaxi acquisit continu expect
revenu driven organ oper growth vs guidanc
organ oper growth estim
increas price target base ev/ebitda multipl
ebitda estim project net debt
share outstand price target also support appli price-to-earnings multipl
ep estim valuat support
long-term discount cash flow dcf valuat analysi use termin growth rate
wacc
zoeti inc page
guidanceupdatedprevi million except per share fy oper cost sale sg interest expens andoth tax rate adj dilut net signific item andacquisition-rel dilut
believ invest zoeti involv follow risk
increas restrict ban use antibiot use growth promot
livestock fda work phase-out use medic import antibacteri
anim feed growth promot chang produc behavior increas regul
could advers impact zoetiss antibacteri product sale
lead chang underli market demand product
chang util product relat protein consumpt chang
consum spend habit diet protein consumpt could advers effect
zoeti busi
infecti diseas outbreak variou infecti diseas avian flu swine flu
etc could lead cull herd reduct use product
cash pay busi therefor chang economi input cost commod
price could neg impact produc abil buy product
industri consolid increas competit continu consolid
anim health industri could lead increas competit result price pressur
could neg impact margin profit
foreign currenc fluctuat approxim zoeti busi deriv
outsid creat foreign currenc risk
zoeti inc page
dcf analysi tax free pv valuetermin termin less compani data craig-hallum capit group llc estimatestermin growthwacc
page
zoetiscraig-hallum capit groupincom statement mm except per share kevin ellich oper oper oper tax net incom attr non-controlling incom attribut ebitda analysi oper incom attribut non-controlling oper incom attribut compani report craig-hallum capit group llc estimatesnovemb requir disclosur
